References
- 1. Morita, S. et al: Prevalence of Non-alcoholic Fatty Liver Diseaseand Steatohepatitis Risk Factors in Patients Undergoing Bariatric Surgery, Obes Surg 2015, 25(12), pp.2335–234310.1007/s11695-015-1696-5
- 2. Younossi, Z.M. et al: Global Epidemiology of Non-Alcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence and Outcomes, Hepatology 2016, 64(1),pp. 73-8410.1002/hep.28431
- 3. Lonardo, A. et al: Non-alcoholic fatty liver disease and risk of cardiovascular disease, Metabolism 2015, 65(8),pp. 1136-115010.1016/j.metabol.2015.09.017
- 4. Musso, G. et al: Metaanalysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity, Ann Med 2011, 43, pp. 617-64910.3109/07853890.2010.518623
- 5. Yki-Jarvinen, H.: Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome, Lancet Diabetes Endocrinol 2014, 2(11), pp. 901–91010.1016/S2213-8587(14)70032-4
- 6. [6] Bertolotti, M. Et al:Nonalcoholic fatty liver disease and aging: epidemiology to management, World J Gastroenterol 2014, 20(39), pp. 14185–1420410.3748/wjg.v20.i39.14185420234825339806
- 7. Lorenz, M.W. et al: Prediction of clinical cardiovascular events with carotid intima-media thickness:a systematic review and meta-analysis, Circulation 2007, 115, pp. 459–46710.1161/CIRCULATIONAHA.106.62887517242284
- 8. Williamson, R.M. et al: Edinburgh Type 2 Diabetes Study Investigators. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: The Edinburgh Type 2 Diabetes Study, Diabetes Care 2011, 34, pp. 1139-114410.2337/dc10-2229311448921478462
- 9. Dai, W. et al: Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A metaanalysis, Medicine (Baltimore) 2017, 96(39)10.1097/MD.0000000000008179562631828953675
- 10. [10] Bellentani, S.; Tiribelli, C.: Epidemiology and risk factors for fatty liver. In: Leuschner U, James OFW, Dancyguer H (eds.). Steatohepatitis (NASH and ASH), Kluwer Academic Publishers: Dordrecht 2001, pp. 3-10
- 11. Vernon, G. et al: Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults, Aliment Pharmacol Ther 2011, 34(3), pp. 274–28510.1111/j.1365-2036.2011.04724.x21623852
- 12. Targher, G.; Arcaro, G.: Non-alcoholic fatty liver disease and increased risk of cardiovascular disease, Atherosclerosis 2007, 191, pp. 235–24010.1016/j.atherosclerosis.2006.08.02116970951
- 13. McKimmie, R.L. et al: Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study, Am J Gastroenterol 2008, 103, pp. 3029-303510.1111/j.1572-0241.2008.02188.x363896118853970
- 14. Ryoo, J.H. et al: Clinical association between non-alcoholic fatty liverdisease and the development of hypertension, J Gastroenterol Hepatol 2014, 29(11), pp.1926-193110.1111/jgh.1264324910023